| 12/04/2025 15:30 |
Announcement of Presentation at The 4th Annual Meeting of The Japanese Antibody Society |
| 12/01/2025 15:30 |
Notice of Joint Research Agreement with Eurus Therapeutics Inc. for the Utilization of PPMX Antibody Library |
| 11/18/2025 16:00 |
Presentation Material for FY2026/3 First Half Business Results |
| 11/14/2025 15:30 |
Notice of Extension of Investigator-Initiated Phase I/II Clinical Trial Period for PPMX-T003 in Aggressive NK-Cell Leukemia (ANKL) |
| 11/14/2025 15:30 |
Notice on Recording of Non-operating Income, Non-operating Expenses, and Extraordinary Losses |
| 11/14/2025 15:30 |
Non-consolidated Summary of Financial Results for the Second Quarter of the Fiscal Year Ending March 31, 2026 |
| 11/05/2025 15:30 |
Notice Regarding Execution of Joint Research Agreement between PPMX and ASKA Pharmaceutical for Creation of Novel Antibody Drugs |
| 10/08/2025 15:30 |
Announcement of New Antibody and Reagent Product Launch |
| 09/18/2025 15:30 |
Announcement of Acceptance for Three Poster Presentations at the 4th Annual Meeting of the Japan Antibody Society |
| 08/14/2025 15:30 |
Non-consolidated Summary of Financial Results for the First Quarter of the Fiscal Year Ending March 31, 2026 |
| 08/14/2025 15:30 |
Business Results Summary for Q1 FY2026/03 |
| 08/14/2025 15:30 |
Notice on Recording of Non-operating Income, Non-operating Expenses, and Extraordinary Losses |
| 07/08/2025 15:30 |
Notice of Acceptance for Presentation at the 84th Annual Meeting of the Japanese Cancer Association |
| 06/24/2025 15:30 |
Publication of Iron-Mediated Cell Cycle Regulation Related to PPMX-T003: Dr. Yanagiya et al. Report in Redox Biology |
| 05/30/2025 13:00 |
PPMX-T003: Announcement of Publication of Paper Co-authored by Hyogo Medical University and Perseus Proteomics on the results of basic studies for the |
| 05/21/2025 15:30 |
Notice of Reduction of Capital Stock and Capital Reserve and Appropriation of Surplus |
| 05/21/2025 15:30 |
Announcement on Change of Certified Public Accountant |
| 05/19/2025 16:00 |
Presentation Material for FY2024 Business Results |
| 05/15/2025 15:30 |
Notice on Recording of Non-operating Income, Non-operating Expenses, and Extraordinary Losses |
| 05/15/2025 15:30 |
Non-consolidated Summary of Financial Results for the Fiscal Year Ended March 31, 2025 |
| 05/09/2025 16:05 |
Announcement of Launch of Antibodies Research Support Service:~ Screening/Production of Antibodies Using VHH Antibody Library ~ |
| 04/25/2025 15:30 |
Announcement of Sales Launch of New Antibodies/Reagents |
| 04/18/2025 15:30 |
Announcement of Launch of Joint Research on Antibody Drug Discovery through Machine Learning with Institute of Science Tokyo |
| 03/31/2025 15:30 |
Notice on Full-Year Business Results Forecasts |
| 03/18/2025 15:30 |
PPMX-T003: Notice on Completion of Clinical Study Report of Phase I Clinical Trial among Polycythemia Vera Patients |
| 02/26/2025 12:30 |
(Amendment) Amendment to "PPMX-T003: Selection as FY2026/3 Project Promoting Support for Drug Discovery Support Program for Orphan drug prior to the |
| 02/26/2025 10:45 |
PPMX-T003: Selection as FY2026/3 Project Promoting Support for Drug Discovery Support Program for Orphan drug prior to the Designation by AMED |
| 02/14/2025 15:35 |
Notice on Recording of Non-operating Income, Non-operating Expenses, and Extraordinary Losses |
| 02/14/2025 15:35 |
Non-consolidated Summary of Financial Results for the Third Quarter of the Fiscal Year Ending March 31, 2025 |
| 12/12/2024 12:30 |
PPMX-T003: Announcement on Extension of Investigator-led Phase I/II Clinical Trial for Aggressive NK-cell Leukemia (ANKL) |
| 12/10/2024 15:30 |
Announcement of Presentation of PPMX-T003 Phase I of Polycythemia Vera at 66th ASH Annual Meeting and Exposition |
